Tamiflu and Neutropenic sepsis - a phase IV clinical study of FDA data

Summary:

Neutropenic sepsis is found among people who take Tamiflu, especially for people who are female, 40-49 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Tamiflu and have Neutropenic sepsis. It is created by eHealthMe based on reports of 20,281 people who have side effects when taking Tamiflu from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

20,281 people reported to have side effects when taking Tamiflu.
Among them, 37 people (0.18%) have Neutropenic sepsis.

What is Tamiflu?

Tamiflu has active ingredients of oseltamivir phosphate. It is often used in the flu. eHealthMe is studying from 21,207 Tamiflu users for its effectiveness, alternative drugs and more.

What is Neutropenic sepsis?

Neutropenic sepsis (whole body infection is caused by a condition in which the number of white blood cells (called neutrophils) in the blood is low. neutrophils help the body to fight infection) is found to be associated with 960 drugs and 648 conditions by eHealthMe.

Number of Tamiflu and Neutropenic sepsis reports submitted per year:

Time on Tamiflu when people have Neutropenic sepsis *:

Gender of people who have Neutropenic sepsis when taking Tamiflu *:

female: 100 %
male: 0.0 %

Age of people who have Neutropenic sepsis when taking Tamiflu *:

Common drugs people take besides Tamiflu *:

Common side effects people have besides Neutropenic sepsis *:

Taste - Impaired: 33 people, 89.19%
Mood Swings (an extreme or rapid change in mood): 33 people, 89.19%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 33 people, 89.19%
Constipation: 33 people, 89.19%
Fatigue (feeling of tiredness): 33 people, 89.19%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 33 people, 89.19%
Glossodynia (a burning or painful sensation in the tongue): 33 people, 89.19%
Sleep Disorder: 33 people, 89.19%
Hypoaesthesia Oral (reduced sense of touch or sensation in mouth): 33 people, 89.19%
Joint Pain: 33 people, 89.19%

Common conditions people have *:

Spinal Pain (pain in spine): 32 people, 86.49%
Itching: 32 people, 86.49%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 32 people, 86.49%
Abdominal Pain: 32 people, 86.49%
Menopausal Symptoms: 31 people, 83.78%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 28 people, 75.68%
Lower Respiratory Tract Infection: 15 people, 40.54%
Genital Herpes (herpes infection of genital): 15 people, 40.54%
Breast Cancer Metastatic: 14 people, 37.84%
Joint Pain: 9 people, 24.32%

* Approximation only. Some reports may have incomplete information.

Do you take Tamiflu and have Neutropenic sepsis?

Check whether Neutropenic sepsis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Neutropenic sepsis and when was it recovered:

Neutropenic sepsis in Tamiflu

Expand to all the drugs that have ingredients of oseltamivir phosphate:

Neutropenic sepsis and drugs with ingredients of oseltamivir phosphate

Alternative drugs to, pros and cons of Tamiflu:

Tamiflu (21,207 reports)

Common Tamiflu side effects:

Browse all side effects of Tamiflu:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Neutropenic sepsis treatments and more:

Neutropenic sepsis (8,271 reports)

COVID vaccines that are related to Neutropenic sepsis:

Common drugs associated with Neutropenic sepsis:

How the study uses the data?

The study uses data from the FDA. It is based on oseltamivir phosphate (the active ingredients of Tamiflu) and Tamiflu (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.